2 min read
Operationalizing Adaptive Design for FDA's One-Trial Era
Operationalizing Adaptive Design for FDA's One-Trial Era
October 20, 2026 : 11:00 AM ET
On February 18, 2026, the FDA...
China is rapidly becoming one of the most influential forces in global drug development—but bringing innovative therapies to patients worldwide requires more than scientific progress. It requires a regulatory strategy built for global success.
In the latest Scope of Things podcast from SCOPE Summit, Veristat's Daphne Smyth, VP of Global Regulatory Affairs, discusses how China's biopharma ecosystem is evolving, why more companies are looking beyond domestic approvals, and what sponsors need to consider when planning development programs for the U.S., Europe, and other international markets.
In the conversation, Daphne explores:
2 min read
Sep 22, 2026 Veristat Events
On February 18, 2026, the FDA...
2 min read
Aug 26, 2026 Veristat Events